

CRF Errors Corrected by the STIC Systems Branch

Serial Number: 09/852,424

0590
1023

Processing Date: 10-25-01 #17
Edited by: M. Spencer
Verified by: _____ (STIC staff)

- ☐ Changed a file from non-ASCII to ASCII
- ☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.
- ☐ Edited a format error in the Current Application Data section, specifically: _____
- ☐ Edited the Current Application Data section with the actual current number. The number input by the applicant was ☐ the prior application data; or ☐ other _____
- ☐ Added the mandatory heading and subheadings for "Current Application Data".
- ☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.
- ☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically: _____
- ☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were: _____
- ☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited: _____
- ☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.
- ☐ Inserted colons after headings/subheadings. Headings edited included: _____
- ☐ Deleted extra, invalid, headings used by an applicant, specifically: _____
- ☒ Deleted: ☒ non-ASCII "garbage" at the beginning end of files; ☐ secretary initials/filename at end of file; ☐ page numbers throughout text; ☐ other invalid text, such as _____
- ☐ Inserted mandatory headings, specifically: _____
- ☐ Corrected an obvious error in the response, specifically: _____
- ☐ Edited identifiers where upper case is used but lower case is required, or vice versa.
- ☐ Corrected an error in the Number of Sequences field, specifically: _____
- ☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.
- ☐ Deleted **ending** stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____
- ☐ Other: _____

**OIP E
ENTERED**

***Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.**

3/1/95

OIPE

RAW SEQUENCE LISTING

DATE: 10/25/2001

PATENT APPLICATION: US/09/852,424

TIME: 13:56:18

Input Set : A:\pto_ms.txt

Output Set: N:\CRF3\10252001\I852424.raw

3 <110> APPLICANT: The University of British Columbia; and
 4 Chemokine Therapeutics Corporation
 6 <120> TITLE OF INVENTION: CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS
 8 <130> FILE REFERENCE: 80021-257
 10 <140> CURRENT APPLICATION NUMBER: US 09/852,424
 C--> 11 <141> CURRENT FILING DATE: 2001-09-26
 13 <150> PRIOR APPLICATION NUMBER: CA 2,305,787
 14 <151> PRIOR FILING DATE: 2000-05-09
 16 <150> PRIOR APPLICATION NUMBER: US 60/205,467
 17 <151> PRIOR FILING DATE: 2000-05-19
 19 <160> NUMBER OF SEQ ID NOS: 135
 21 <170> SOFTWARE: PatentIn Ver. 2.0
 23 <210> SEQ ID NO: 1
 24 <211> LENGTH: 67
 25 <212> TYPE: PRT
 26 <213> ORGANISM: Artificial Sequence
 28 <220> FEATURE:
 29 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
 30 Laboratory
 32 <400> SEQUENCE: 1
 33 Lys Gly Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
 34 1 5 10 15
 36 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
 37 20 25 30
 39 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
 40 35 40 45
 42 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
 43 50 55 60
 45 Ala Leu Asn
 46 65
 49 <210> SEQ ID NO: 2
 50 <211> LENGTH: 67
 51 <212> TYPE: PRT
 52 <213> ORGANISM: Artificial Sequence
 54 <220> FEATURE:
 55 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
 56 Laboratory
 58 <400> SEQUENCE: 2
 59 Lys Gly Val Ser Pro Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
 60 1 5 10 15
 62 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
 63 20 25 30
 65 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
 66 35 40 45
 68 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
 69 50 55 60
 71 Ala Leu Asn

RAW SEQUENCE LISTING

DATE: 10/25/2001

PATENT APPLICATION: US/09/852,424

TIME: 13:56:18

Input Set : A:\pto_ms.txt

Output Set: N:\CRF3\10252001\I852424.raw

```

72 65
75 <210> SEQ ID NO: 3
76 <211> LENGTH: 67
77 <212> TYPE: PRT
78 <213> ORGANISM: Artificial Sequence
80 <220> FEATURE:
81 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
82   Laboratory
84 <400> SEQUENCE: 3
85 Lys Gly Val Ser Leu Pro Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
86   1             5             10             15
88 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
89             20             25             30
91 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
92             35             40             45
94 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
95   50             55             60
97 Ala Leu Asn
98 65
101 <210> SEQ ID NO: 4
102 <211> LENGTH: 67
103 <212> TYPE: PRT
104 <213> ORGANISM: Artificial Sequence
106 <220> FEATURE:
107 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
108   Laboratory
110 <400> SEQUENCE: 4
111 Lys Gly Val Ser Leu Ser Pro Arg Cys Pro Cys Arg Phe Phe Glu Ser
112   1             5             10             15
114 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
115             20             25             30
117 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
118             35             40             45
120 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
121   50             55             60
123 Ala Leu Asn
124 65
127 <210> SEQ ID NO: 5
128 <211> LENGTH: 67
129 <212> TYPE: PRT
130 <213> ORGANISM: Artificial Sequence
132 <220> FEATURE:
133 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
134   Laboratory
136 <400> SEQUENCE: 5
137 Lys Gly Val Ser Leu Ser Tyr Pro Cys Pro Cys Arg Phe Phe Glu Ser
138   1             5             10             15
140 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
141             20             25             30

```


RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001

TIME: 13:56:18

Input Set : A:\pto_ms.txt

Output Set: N:\CRF3\10252001\I852424.raw

143 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
 144 35 40 45
 146 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
 147 50 55 60
 149 Ala Leu Asn
 150 65

153 <210> SEQ ID NO: 6

154 <211> LENGTH: 67

155 <212> TYPE: PRT

156 <213> ORGANISM: Artificial Sequence

158 <220> FEATURE:

159 <221> NAME/KEY: MUTAGEN

160 <222> LOCATION: (5)

161 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
 162 disclosure for possible structures for P*

164 <220> FEATURE:

165 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
 166 Laboratory

168 <400> SEQUENCE: 6

W--> 169 Lys Gly Val Ser Xaa Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
 170 1 5 10 15
 172 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
 173 20 25 30
 175 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
 176 35 40 45
 178 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
 179 50 55 60
 181 Ala Leu Asn
 182 65

185 <210> SEQ ID NO: 7

186 <211> LENGTH: 67

187 <212> TYPE: PRT

188 <213> ORGANISM: Artificial Sequence

190 <220> FEATURE:

191 <221> NAME/KEY: MUTAGEN

192 <222> LOCATION: (6)

193 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
 194 disclosure for possible structures for P*

196 <220> FEATURE:

197 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
 198 Laboratory

200 <400> SEQUENCE: 7

W--> 201 Lys Gly Val Ser Leu Xaa Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
 202 1 5 10 15
 204 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
 205 20 25 30
 207 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
 208 35 40 45
 210 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001

TIME: 13:56:18

Input Set : A:\pto_ms.txt

Output Set: N:\CRF3\10252001\I852424.raw

```

211      50      55      60
213 Ala Leu Asn
214 65
217 <210> SEQ ID NO: 8
218 <211> LENGTH: 67
219 <212> TYPE: PRT
220 <213> ORGANISM: Artificial Sequence
222 <220> FEATURE:
223 <221> NAME/KEY: MUTAGEN
224 <222> LOCATION: (7)
225 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
226 disclosure for possible structures for P*
228 <220> FEATURE:
229 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
230 Laboratory
232 <400> SEQUENCE: 8
W--> 233 Lys Gly Val Ser Leu Ser Xaa Arg Cys Pro Cys Arg Phe Phe Glu Ser
234 1 5 10 15
236 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
237 20 25 30
239 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
240 35 40 45
242 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
243 50 55 60
245 Ala Leu Asn
246 65
249 <210> SEQ ID NO: 9
250 <211> LENGTH: 67
251 <212> TYPE: PRT
252 <213> ORGANISM: Artificial Sequence
254 <220> FEATURE:
255 <221> NAME/KEY: MUTAGEN
256 <222> LOCATION: (8)
257 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
258 disclosure for possible structures for P*
260 <220> FEATURE:
261 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
262 Laboratory
264 <400> SEQUENCE: 9
W--> 265 Lys Gly Val Ser Leu Ser Tyr Xaa Cys Pro Cys Arg Phe Phe Glu Ser
266 1 5 10 15
268 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
269 20 25 30
271 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
272 35 40 45
274 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
275 50 55 60
277 Ala Leu Asn
278 65

```


RAW SEQUENCE LISTING

DATE: 10/25/2001

PATENT APPLICATION: US/09/852,424

TIME: 13:56:18

Input Set : A:\pto_ms.txt

Output Set: N:\CRF3\10252001\I852424.raw

```

281 <210> SEQ ID NO: 10
282 <211> LENGTH: 66
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <221> NAME/KEY: MUTAGEN
288 <222> LOCATION: (5)
289 <223> OTHER INFORMATION: Xaa=Btd=Bicyclic Turned Dipeptide. See Page 17 of
290 disclosure for possible structures for Btd
292 <220> FEATURE:
293 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
294 Laboratory
296 <400> SEQUENCE: 10
W--> 297 Lys Gly Val Ser Xaa Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser His
298      1              5              10              15
300 Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro Asn
301              20              25              30
303 Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln Val
304              35              40              45
306 Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala
307      50              55              60
309 Leu Asn
310 65
313 <210> SEQ ID NO: 11
314 <211> LENGTH: 66
315 <212> TYPE: PRT
316 <213> ORGANISM: Artificial Sequence
318 <220> FEATURE:
319 <221> NAME/KEY: MUTAGEN
320 <222> LOCATION: (6)
321 <223> OTHER INFORMATION: Xaa=Btd=Bicyclic Turned Dipeptide. See Page 17
322 of disclosure for possible structures for Btd
324 <220> FEATURE:
325 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
326 Laboratory
328 <400> SEQUENCE: 11
W--> 329 Lys Gly Val Ser Leu Xaa Arg Cys Pro Cys Arg Phe Phe Glu Ser His
330      1              5              10              15
332 Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro Asn
333              20              25              30
335 Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln Val
336              35              40              45
338 Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala
339      50              55              60
341 Leu Asn
342 65
345 <210> SEQ ID NO: 12
346 <211> LENGTH: 66
347 <212> TYPE: PRT

```

Use of n and / or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to ensure a corresponding explanation is present in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001

TIME: 13:56:19

Input Set : A:\pto_ms.txt

Output Set: N:\CRF3\10252001\I852424.raw

L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:169 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:201 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:233 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:265 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:297 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:329 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:361 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:448 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:555 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:578 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:601 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:647 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:667 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:687 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:763 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:783 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:803 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:843 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:863 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:883 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:999 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44
L:1027 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45
L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46
L:1083 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47
L:1111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
L:1139 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
L:1167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
L:1189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51
L:1230 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:53
L:1271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:55
L:1312 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57
L:1359 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59
L:1384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60
L:1412 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:61
L:1437 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:62
L:1465 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:63
L:1490 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:64
L:1518 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:65
L:1543 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:66
L:1571 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:67
L:1596 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68
L:1624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:69
L:1649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:70
L:1677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:71
L:1702 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:72

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001

TIME: 13:56:19

Input Set : A:\pto_ms.txt

Output Set: N:\CRF3\10252001\I852424.raw

L:1784 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76

L:1809 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77

L:2024 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/852,424

DATE: 10/10/2001

TIME: 11:17:41

Input Set : A:\80021-257.us.sequence listing.txt

Output Set: N:\CRF3\10102001\I852424.raw

3 <110> APPLICANT: The University of British Columbia; and
 4 Chemokine Therapeutics Corporation
 6 <120> TITLE OF INVENTION: CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS
 8 <130> FILE REFERENCE: 80021-257
 10 <140> CURRENT APPLICATION NUMBER: US 09/852,424
 C--> 11 <141> CURRENT FILING DATE: 2001-09-26
 13 <150> PRIOR APPLICATION NUMBER: CA 2,305,787
 14 <151> PRIOR FILING DATE: 2000-05-09
 16 <150> PRIOR APPLICATION NUMBER: US 60/205,467
 17 <151> PRIOR FILING DATE: 2000-05-19
 19 <160> NUMBER OF SEQ ID NOS: 135
 21 <170> SOFTWARE: PatentIn Ver. 2.0

**Does Not Comply
 Corrected Diskette Needed**

ERRORED SEQUENCES

3323 <210> SEQ ID NO: 135
 3324 <211> LENGTH: 31
 3325 <212> TYPE: PRT
 3326 <213> ORGANISM: Artificial Sequence
 3328 <220> FEATURE:
 3329 <221> NAME/KEY: DOMAIN
 3330 <222> LOCATION: (24)..(28)
 3331 <223> OTHER INFORMATION: K28/E24 Lactamization - domain cyclized
 3333 <220> FEATURE:
 3334 <221> NAME/KEY: MOD_RES
 3335 <222> LOCATION: (31)
 3336 <223> OTHER INFORMATION: AMIDATION
 3338 <220> FEATURE:
 3339 <221> NAME/KEY: DOMAIN
 3340 <222> LOCATION: (15)..(18)
 3341 <223> OTHER INFORMATION: The number of glycines linking the N- and
 3342 C-terminal amino acids may be varied.
 3344 <220> FEATURE:
 3345 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
 3346 Laboratory
 3348 <400> SEQUENCE: 135
 3349 Lys Gly Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly
 3350 1 5 10 15
 3352 Gly Gly Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn
 3353 20 25 30
 E--> 3356 59

*Delete miscellaneous material
 from end of file.*

Use of n and / or Xaa has been detected in the
 Sequence Listing. Review the Sequence Listing
 to ensure a corresponding explanation is present
 in the <220> to <223> fields of each sequence
 using n or Xaa.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/852,424

DATE: 10/10/2001

TIME: 11:17:42

Input Set : A:\80021-257.us.sequence listing.txt

Output Set: N:\CRF3\10102001\I852424.raw

L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:169 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:201 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:233 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:265 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:297 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:329 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:361 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:448 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:555 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:578 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:601 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:647 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:667 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:687 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:763 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:783 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:803 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:843 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:863 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:883 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:999 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44
L:1027 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45
L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46
L:1083 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47
L:1111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
L:1139 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
L:1167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
L:1189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51
L:1230 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:53
L:1271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:55
L:1312 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57
L:1359 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59
L:1384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60
L:1412 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:61
L:1437 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:62
L:1465 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:63
L:1490 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:64
L:1518 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:65
L:1543 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:66
L:1571 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:67
L:1596 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68
L:1624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:69
L:1649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:70
L:1677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:71
L:1702 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:72

VERIFICATION SUMMARY

DATE: 10/10/2001

PATENT APPLICATION: US/09/852,424

TIME: 11:17:42

Input Set : A:\80021-257.us.sequence listing.txt

Output Set: N:\CRF3\10102001\I852424.raw

L:1784 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76
L:1809 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2024 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86
L:3356 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:135